Press release

Press release

December 17, 2019

Follicum annnouces positive human ex vivo data from preclinical diabetes studies of new class of FOL peptides

Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed […]

December 16, 2019

Follicum receives patent grant in the U.S. for stimulation of hair growth using FOL-005

Follicum announced on September 17, 2019 that the Company had received a so-called Notice of Allowance from the US Patent and Trademark Office (“USPTO”) regarding the patent application “Novel Compositions and Uses Thereof”. Follicum today announces that the patent has now formally been granted by the USPTO. The patent number is US 10,517,932 and the […]

October 24, 2019

Follicum receives Eurostars grant to develop the company’s first-in-class treatment of diabetes

Follicum today announces that the company’s application for a Eurostars grant comprising the development of a first-in-class treatment for diabetes has been approved. Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ). The grant comprising just under EUR 0.7 M commences December […]

October 21, 2019

Correction: Follicum successfully completes toxicology studies for upcoming FOL-005 Phase IIa clinical trial in patients with hair loss

Follicum today announces that the company has successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005. The company expects to be ready for the start of the clinical study in patients with hairloss (alopecia) in early 2020. Preparations for the clinical trial […]

October 21, 2019

Follicum successfully completes toxicology studies for upcoming FOL-005 Phase IIa clinical trial in patients with hair loss

Follicum today announces that the company has successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005. The company expects to be ready for the start of the clinical study in patients with hairloss (alopecia) in early 2020. Preparations for the clinical trial […]

September 26, 2019

Follicum initiates collaboration with Bioglan for the production of FOL-005 cream for upcoming clinical trial on patients with hair loss

Lund, Sweden, September 26. Follicum today announces the signing of a cooperation agreement with Bioglan AB for the production of clinical trial material of Follicum’s new, cream-like formulation of FOL-005 for topical treatment. The formulation will be used in the Phase II clinical trial on hair loss, which is expected to start in the beginning […]

September 17, 2019

Follicum AB receives Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005

Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 16/176,201 which when granted confers expanded protection for Follicum’s product candidate FOL-005. Follicum has already two granted US patents in this patent family (US 9,381,149 and US 10,137,169), conferring protection for different forms of FOL-005. […]

July 11, 2019

Follicum receives approval of patent in Korea

Follicum AB (”Follicum”) today announces that the Korean patent office (”KIPO”) has approved the company’s patent application for stimulation of hair growth. With the approval in Korea, patent number 10-1992282, Follicum has a patent protection in Korean up to and including year 2032. The patent protects the company’s peptides in general and for stimulation of […]

June 17, 2019

Successful meeting with the German Medicines Agency regarding preparations for topical phase II scalp study

Follicum AB (“Follicum” or “company”) today report that the company has had a successful scientific advisory meeting regarding the hair project FOL-005, with the German authority, BfArM. In accordance with the previously announced timetable, Follicum has prepared a background document for scientific advice with the German Medicinces agency BfArM. The meeting discussed which additional toxicity […]